Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial

Malignant pleural mesothelioma (MPM) is a cancer derived from mesothelial cells growing in the thoracic cavity with few treatment options. Despite the use of multi-modality approaches, the median survival after diagnosis does not exceed two years.1Stahel R.A. Riesterer O. Xyrafas A. et al.Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised,...